<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323126</url>
  </required_header>
  <id_info>
    <org_study_id>CEGF816X2201C</org_study_id>
    <secondary_id>2014-003731-20</secondary_id>
    <nct_id>NCT02323126</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer</brief_title>
  <acronym>EGF816</acronym>
  <official_title>A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: National Agency for the Safety of Medicines and Health Products (MSNA)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Nivolumab in combination with EGF816 and of
      Nivolumab in combination with INC280 in previously treated NSCLC patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has two arms:

      Arm 1 (EGF816 + nivolumab) is on hold and therefore this arm is currently closed to new
      enrollment.

      Arm 2 (INC280 + nivolumab) is open and enrolling as planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) rate using RECIST version1.1</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Continuously during study until 100 days after post study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety of EGF816 and Nivolumab and INC280 and Nivolumab by looking at hematology and chemistry laboratory parameters, vital signs, and electrocardiograms (ECGs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>baseline, every 8 weeks up to cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>baseline, every 8 weeks upto cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>baseline, every 8 weeks upto cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Start of treatment until death, average 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic parameters (AUClast, AUC0-t,AUCtau,Cmax, Tmax)</measure>
    <time_frame>Cycle 1: Day1, Day 8, Day 15 and Cycle 2: Day 1, Cycle 4: Day 1 Cycle 6: Day 1 and Cycle 8: Day 1 Subsequent cycles (nivolumab only): every 8th cycle until discontinuation of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab and EGF816</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 (EGF816 + nivolumab) is on hold and therefore this arm is currently closed to new enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab and INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 (INC280 + nivolumab) is open and enrolling as planned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <arm_group_label>Nivolumab and EGF816</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>Nivolumab and INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab and EGF816</arm_group_label>
    <arm_group_label>Nivolumab and INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained prior to any screening procedures

          -  Presence of at least one measurable lesion according to RECIST v.1.1

          -  ECOG performance status ≤ 2

          -  Patients with histologically documented locally advanced, recurrent and/or metastatic
             NSCLC

          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.
             cMET positivity for Group 2 at any point in treatment; or EGFR T790M positivity post
             progression on EGFR TKI) must be provided for analysis

        Group 1 patients:

          -  Patients with EGFR T790M NSCLC (adenocarcinoma)

          -  Documented progression of disease according to RECIST v1.1 following primary standard
             of care (e.g. erlotinib, gefitinib)

        Group 2 patients:

          -  Patients with EGFR wild-type, cMET positive NSCLC

          -  Documented progression of disease according to RECIST v1.1 following primary standard
             of care (e.g. platinum doublet).

        Exclusion Criteria:

        For Group1:

        - Patients who have received more than one prior line of EGFR TKI therapy1

        For Group 2:

          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy

          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been
             completed and serial evaluation by CT (with contrast enhancement) or MRI over a
             minimum of one month demonstrates the disease to be stable and if the patient remains
             must have no need for treatment with steroids

          -  Patients who require emergent use of systemic steroids, chronic use of prednisone
             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or
             radiotherapy.

          -  History of allergy or hypersensitivity to nivolumab components

          -  Patients with an active, known or suspected autoimmune disease. Patients with type I
             diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll

          -  Patients with a condition requiring chronic systemic treatment with either
             corticosteroids(&gt; 10 mg daily prednisone equivalent) or other immunosuppressive
             medications within 14 days of treatment start. Inhaled or topical steroids, and
             adrenal replacement steroid doses&gt; 10 mg daily prednisone equivalent, are permitted
             in the absence of active autoimmune disease

          -  Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS)

          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
             chronic infection

          -  Patients with interstitial lung disease that is symptomatic or may interfere with the
             detection or management of suspected drug-related pulmonary toxicity

          -  Patients with interstitial lung disease that is symptomatic or may interfere with the
             detection or management of suspected drug-related pulmonary toxicity

        Prior therapy:

          -  Patients who have been treated with prior PD-1 and PD-L1 agents

          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:
             Previous treatment with afatinib may be allowable after discussions between Novartis
             and Investigator.

          -  Patients with the following laboratory abnormalities:

               -  Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L

               -  Hemoglobin (Hgb) &lt;9 g/dL

               -  Platelets &lt;100 x 109/L

               -  Total bilirubin &gt;1.5 x upper limit of normal (ULN). For patients with Gilbert's
                  syndrome total bilirubin &gt;2.5 x upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;3 x ULN

               -  Serum creatinine &gt;1.5 x ULN and/or measured or calculated creatinine clearance
                  &lt;75% LLN

        Other protocol-related inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Onc Department</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Perna</last_name>
      <phone>205-934-5092</phone>
      <email>cperna@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Francisco Robert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kennedy</last_name>
      <phone>617-724-1223</phone>
      <email>EAKENNEDY@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lecia Sequist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute Oncology Dept</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delois DeShazo</last_name>
      <phone>980-442-2383</phone>
      <email>delois.deshazo@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Mileham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NKI-AVL, Department of Thoracic-Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.F. Smit, Prof.</last_name>
      <phone>0031-20-5122958</phone>
      <email>e.smit@nki.nl</email>
    </contact>
    <investigator>
      <last_name>E.F. Smit, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>December 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small cell lung cancer,</keyword>
  <keyword>NSCLC,</keyword>
  <keyword>EGFR-mutated,</keyword>
  <keyword>EGF816,</keyword>
  <keyword>INC280,</keyword>
  <keyword>Nivolumab,</keyword>
  <keyword>EGFR-T790M NSCLC,</keyword>
  <keyword>EGFR wild-type (wt),</keyword>
  <keyword>cMET positive NSCLC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
